Pregled bibliografske jedinice broj: 1041298
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot
Intragastric Application of Aspirin, Clopidogrel, Cilostazol, and BPC 157 in Rats: Platelet Aggregation and Blood Clot // Oxidative Medicine and Cellular Longevity, 2019 (2019), 1-9 doi:10.1155/2019/9084643 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1041298 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Intragastric Application of Aspirin,
Clopidogrel, Cilostazol, and BPC 157 in Rats:
Platelet Aggregation and Blood Clot
Autori
Konosic, Sanja ; Petricevic, Mate ; Ivancan, Visnja ; Konosic, Lucija ; Goluza, Eleonora ; Krtalic, Branimir ; Drmic, Domagoj ; Stupnisek, Mirjana ; Seiwerth, Sven ; Sikiric, Predrag
Izvornik
Oxidative Medicine and Cellular Longevity (1942-0900) 2019
(2019);
1-9
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
aspirin ; clopidogrel ; cilostazol ; BPC 157
Sažetak
We suggest that the stable gastric pentadecapeptide BPC 157 may rescue thrombocyte function. We focused on the antithrombotic agent aspirin, clopidogrel, and cilostazol application in rats ; arachidonic acid, ADP, collagen, and arachidonic acid/PGE1 platelet aggregation (aggregometry) and blood clot viscoelastic properties (thromboelastometry) ; and the pentadecapeptide BPC 157. Rats received intragastrically for three days once daily treatment with antithrombotic agents—aspirin (10 mg/kg) or clopidogrel (10 mg/kg) or cilostazol (10 mg/kg). Medication (BPC 157 (10 μg/kg) or an equal volume of saline (5 ml/kg)) was given intragastrically, immediately after each antithrombotic agent application. For multiple electrode aggregometry and modified rotational thromboelastometry studies, blood sampling was at 2 h after last application. Adenosine diphosphate (ADP test 6.5 μM), arachidonic acid (ASPI test 0.5 mM), a combination of arachidonic acid and prostaglandin E1 (ASPI test 0.5 mM and PGE1- test 30 nM), and collagen (COL test 3.2 μg/ml) were used as aggregation agonists. Given with aspirin, clopidogrel, or cilostazol in rats, BPC 157 counteracted their inhibitory effects on aggregation activated by arachidonic acid, ADP, collagen, and arachidonic acid/PGE1. Specifically, this includes recovery of the aggregation induced by arachidonic acid (vs. aspirin, vs. clopidogrel, and vs. cilostazol), arachidonic acid/PGE1 (vs. cilostazol), ADP (vs. clopidogrel), or collagen (vs. clopidogrel). Contrarily, there is no effect on the used tests (extrinsic/intrinsic hemostasis system, the fibrin part of the clot) EXTEM, INTEM, and FIBTEM ; clotting time ; clot formation time ; alpha-angle ; maximum clot firmness ; lysis index after 30 minutes ; and maximum lysis. In conclusion, we revealed that BPC 157 largely rescues thrombocyte function.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Profili:
Mate Petričević
(autor)
Predrag Sikirić
(autor)
Sven Seiwerth
(autor)
Mirjana Stupnišek
(autor)
Branimir Krtalić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE